Pertussis antigens and use thereof in vaccination
AssigneeGlaxosmithkline Biologicals SA
InventorsCindy Castado, Philippe Denoel, Fabrice Godfroid, Jan Poolman
Life of this patent
Estimating the term…
Abstract
The invention provides BASB232 polypeptides and polynucleotides encoding BASB232 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses. The invention further provides immunogenic compositions comprising a plurality of antigens selected from at least two different categories of antigen, having different functions within Bordetella. Examples of such categories of antigen are autotransporter proteins, iron acquisition proteins, lipoproteins, adhesins and toxins/invasins.
Claims13
An immunogenic composition comprising:
- a) a fragment of SEQ ID NO:34, wherein the fragment comprises amino acids 41 to 706 of SEQ ID NO:34;
- b) filamentous haemagglutinin (FHA);
- and
- c) pertussis toxin.
An immunogenic composition comprising:
- a) a fragment of SEQ ID NO:34, wherein the fragment comprises amino acids 60 to 702 of SEQ ID NO:34;
- b) filamentous haemagglutinin (FHA);
- and
- c) pertussis toxin.
An immunogenic composition comprising:
- a) a fragment of SEQ ID NO:34, wherein the fragment comprises amino acids 41 to 706 of SEQ ID NO:34 from which 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, or 50 amino acids have been removed from either or both of the N and C termini;
- b) filamentous haemagglutinin (FHA);
- and
- c) pertussis toxin.
Dependencies are inferred from the claim text.